SCHEMBL2908468

SCHEMBL2908468

CCN1CCN(C(c2ccccc2)c2c[nH]nc2-c2ccccc2F)CC1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
KMT2A Q03164 5/20 0.41
MEN1 O00255 4/20 0.41
ATM Q13315 3/20 0.41
HRH3 Q9Y5N1 1/20 0.41
MAPK1 P28482 2/20 0.39
L3MBTL1 Q9Y468 1/20 0.38
P2RX7 Q99572 1/20 0.37
OPRM1 P35372 2/20 0.37
OPRD1 P41143 2/20 0.37
DRD2 P14416 1/20 0.37
DRD3 P35462 1/20 0.37
OPRK1 P41145 1/20 0.37
OPRL1 P41146 1/20 0.37
MAPT P10636 2/20 0.37
HSP90AA1 P07900 1/20 0.37
GAA P10253 1/20 0.37
LMNA P02545 1/20 0.36
TP53 P04637 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2907391 0.88 OPRM1 (0.50) ALDH1A1SMN1; SMN2KMT2AMEN1HRH3
SCHEMBL2908249 0.85 ALDH1A1 (0.44) ALDH1A1SMN1; SMN2KMT2AMEN1ATM
SCHEMBL2906133 0.83 HSP90AA1 (0.43) ALDH1A1KMT2AMEN1HRH3MAPK1
SCHEMBL2905341 0.82 CHRM2 (0.43) ALDH1A1SMN1; SMN2KMT2AMEN1HRH3
SCHEMBL2908936 0.77 HRH3 (0.39) ALDH1A1KMT2AMEN1HRH3MAPK1
SCHEMBL2902536 0.77 OPRK1 (0.36) KMT2AMEN1ATML3MBTL1OPRM1
SCHEMBL2905013 0.73 MEN1 (0.37) KMT2AMEN1
SCHEMBL13784937 0.72 OPRM1 (0.63) ALDH1A1KMT2AMEN1ATMMAPK1
SCHEMBL2909897 0.72 KCNH2 (0.56) ALDH1A1SMN1; SMN2KMT2AMEN1HRH3
SCHEMBL2905437 0.71 MEN1 (0.34) ALDH1A1KMT2AMEN1OPRM1OPRD1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1611107-B1 1,3,4-SUBSTITUTED PYRAZOLES FOR USE AS 5-HT RECEPTOR ANTAGONISTS IN THE TREATMENT OF PSYCHOSES AND NEUROLOGICAL DISORDERS MERCK PATENT GMBH (DE) 2010-08-18 EP claimed
EP-1611107-B1 1,3,4-SUBSTITUTED PYRAZOLES FOR USE AS 5-HT RECEPTOR ANTAGONISTS IN THE TREATMENT OF PSYCHOSES AND NEUROLOGICAL DISORDERS MERCK PATENT GMBH (DE) 2010-08-18 EP disclosed
US-7566709-B2 1,3,4-Substituted pyrazoles as 5-HT receptor antagonists for the treatment of psychoses and neurological disorders MERCK PATENT GMBH (DE) 2009-07-28 US disclosed
US-20070105871-A1 1,3,4-Substituted pyrazoles as 5-ht receptor antagonists for the treatment of psychoses and neurological disorders MERCK PATENT GMBH (DE) 2007-05-10 US disclosed
CN-1768043-A 1,3,4-substituted pyrazoles for use as 5-ht receptor antagonists in the treatment of psychoses and neurological disorders. MERCK PATENT GMBH (DE) 2006-05-03 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070105871-A1 1,3,4-Substituted pyrazoles as 5-ht receptor antagonists for the treatment of psychoses and neurological disorders HTR1A, HTR1D, HTR5A ALDH1A1 1336/4885SMN1; SMN2 1277/4885KMT2A 2510/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.